| To Evaluate the Renal Protective Effects and Safety of 'Fimasartan and Atorvastatin' or 'Fimasartan, Atorvastatin and Ezetimibe'. (NCT07685054) | Boryung Pharmaceutical Co., Ltd | 2026-08-01 |
| A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015-3 and BR1015-2 Under Fed Conditions (NCT07421414) | Boryung Pharmaceutical Co., Ltd | 2026-04-19 |
| A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015-3 and BR1015-2 Under Fasting Conditions (NCT07421401) | Boryung Pharmaceutical Co., Ltd | 2026-04-13 |
| A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015-1 and BR1015-2 Under Fed Conditions (NCT07421388) | Boryung Pharmaceutical Co., Ltd | 2026-04-09 |
| A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015-1 and BR1015-2 Under Fasting Conditions (NCT07421375) | Boryung Pharmaceutical Co., Ltd | 2026-04-02 |
| A Study of BR1400-1, BR1400-2, BR1400-3, BR1400-4, and BR1400-5 in Patients With Essential Hypertension (NCT07373613) | Boryung Pharmaceutical Co., Ltd | 2026-03-01 |
| A Study of Bosmolisib (BR101801) in Participants With R/R PTCL. (NCT07180771) | Boryung Pharmaceutical Co., Ltd | 2026-02-01 |
| A Study of Second- and Later-line Palliative Chemotherapy in Patients With Metastatic Colorectal Cancer. (NCT07263178) | Boryung Pharmaceutical Co., Ltd | 2025-11-07 |
| A Study of Olanzapine in Participants With Bipolar Disorder. (NCT07263191) | Boryung Pharmaceutical Co., Ltd | 2025-10-30 |
| A Study to Evaluate the Pharmacokinetics and Safety Between "BR3006" and Co-administration of "BR3006A", "BR3006B", and "BR3006C" in Healthy Adult Volunteers (Fed) (NCT07083401) | Boryung Pharmaceutical Co., Ltd | 2025-07-05 |
| A Study to Evaluate the Pharmacokinetics and Safety Between "BR3006" and Co-administration of "BR3006A", "BR3006B", and "BR3006C" in Healthy Adult Volunteers (Fasting) (NCT07083388) | Boryung Pharmaceutical Co., Ltd | 2025-07-03 |
| A Clinical Trial to Evaluate the Safety and Efficacy of Olanzapine Titration Schedule in Patients With Schizophrenia (NCT06821945) | Boryung Pharmaceutical Co., Ltd | 2025-05-30 |
| A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1018 and Coadministration of BR1018A and BR1018B in Healthy Adult Volunteers (NCT06889012) | Boryung Pharmaceutical Co., Ltd | 2025-05-07 |
| A Study to Compare and Evaluate the Pharmacokinetic Characteristics and the Safety Between Administration of BR2021 and BR2021-1 (NCT06867497) | Boryung Pharmaceutical Co., Ltd | 2025-02-24 |
| A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015 and Co-administration of BR1015-3 and BR1015-2 Under Fed Conditions (NCT06744439) | Boryung Pharmaceutical Co., Ltd | 2025-01-09 |
| A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015 and Co-administration of BR1015-1 and BR1015-2 in Healthy Volunteers Fed Conditions (NCT06744062) | Boryung Pharmaceutical Co., Ltd | 2025-01-05 |
| A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015 and Co-administration of BR1015-3 and BR1015-2 Under Fasting Conditions (NCT06744426) | Boryung Pharmaceutical Co., Ltd | 2025-01-04 |
| A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015 and Co-administration of BR1015-1 and BR1015-2 Under Fasting Conditions (NCT06744127) | Boryung Pharmaceutical Co., Ltd | 2025-01-03 |
| A Study to Evaluate the Pharmacokinetics and Safety Between Single Oral Administration of BR3006 and Co-administration of BR3006A, BR3006B and BR3006C in Healthy Adult Volunteers Under Fed Conditions (NCT06890299) | Boryung Pharmaceutical Co., Ltd | 2024-12-05 |
| A Study to Evaluate the Pharmacokinetics and Safety Between Single Oral Administration of BR3006 and Co-administration of BR3006A, BR3006B and BR3006C in Healthy Adult Volunteers Under Fasting Conditions (NCT06890286) | Boryung Pharmaceutical Co., Ltd | 2024-12-01 |
| A Study to Evaluate the Pharmacokinetics and Safety of BR3409 and Co-administration of BR3409-1 and BR3409-2 in Healthy Volunteers Under Fasting Conditions (NCT06879158) | Boryung Pharmaceutical Co., Ltd | 2024-11-10 |
| A Study to Evaluate the Pharmacokinetics and Safety of BR3409 and Co-administration of BR3409-1 and BR3409-2 in Healthy Volunteers Under Fed Conditions (NCT06879132) | Boryung Pharmaceutical Co., Ltd | 2024-11-05 |
| A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1019" and Co-administration of "BR1019-3" and "BR1019-2" in Healthy Volunteers (NCT06636877) | Boryung Pharmaceutical Co., Ltd | 2024-10-23 |
| A Study to Identify the Risk of Non-alcoholic Fatty Liver Disease (NAFLD) in Patients With Type 2 Diabetes in Clinical Practice and to Evaluate the Clinical Usefulness of Dapagliflozin/Pioglitazone Combination Therapy (NCT06649162) | Boryung Pharmaceutical Co., Ltd | 2024-09-30 |
| A Study to Evaluate the Pharmacokinetic, Pharmacodynamic Characteristics and the Safety After Administration by Doses of BR1400-1, BR1400-2, BR1400-3 in Healthy Adult Volunteers (NCT06889064) | Boryung Pharmaceutical Co., Ltd | 2024-09-24 |
| A Study to Evaluate Ethanol-induced Symptoms and Safety in Breast Cancer Patients (NCT06537752) | Boryung Pharmaceutical Co., Ltd | 2024-07-15 |
| A Study to Evaluate the Efficacy and Safety of BR1019A and BR1019B Combination Therapy (NCT06220773) | Boryung Pharmaceutical Co., Ltd | 2024-05-21 |
| A Study to Evaluate the Efficacy and Safety of Co-administrated BR1018B and BR1018C (NCT06165250) | Boryung Pharmaceutical Co., Ltd | 2024-04-17 |
| A Study to Evaluate the Efficacy and Safety of Fixed-Dose Combination of Pitavastatin/Ezetimib (NCT06314919) | Boryung Pharmaceutical Co., Ltd | 2024-03-15 |
| A Study to Compare the Pharmacokinetics and the Safety Between a Fixed-dose Combination Administration of "BR3005" and Co-administration of "BR3005-1" and "BR3005-2" Under Fed Conditions in Healthy Adult Volunteers (NCT06289933) | Boryung Pharmaceutical Co., Ltd | 2024-03-05 |
| A Study to Compare the Pharmacokinetics and the Safety Between a Fixed-dose Combination Administration of "BR3005" and Co-administration of "BR3005-1" and "BR3005-2" Under Fasting Conditions in Healthy Adult Volunteers (NCT06289920) | Boryung Pharmaceutical Co., Ltd | 2024-03-02 |
| A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1019" and Co-administration of "BR1019-1" and "BR1019-2" (NCT06226727) | Boryung Pharmaceutical Co., Ltd | 2024-02-14 |
| A Observational Study to Evaluate the Efficacy and Safety of Pacitol Inj. (NCT06126016) | Boryung Pharmaceutical Co., Ltd | 2023-10-19 |
| A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1015" and Co-administration of "BR1015-1" and "BR1015-2" Under Fed Conditions in Healthy Volunteers (NCT06008015) | Boryung Pharmaceutical Co., Ltd | 2023-09-04 |
| Observational Study to Evaluate the Safety and Efficacy of Zepzelca™ Injection (NCT06021483) | Boryung Pharmaceutical Co., Ltd | 2023-08-16 |
| A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1015" and Co-administration of "BR1015-1" and "BR1015-2" Under Fasting Conditions in Healthy Volunteers (NCT06008028) | Boryung Pharmaceutical Co., Ltd | 2023-08-10 |
| A Study to Evaluate Drug-drug Interactions and Safety Between "BR3006-1", "BR3006-2", and "BR3006-3" in Healthy Volunteers (NCT05951946) | Boryung Pharmaceutical Co., Ltd | 2023-07-22 |
| A Study to Evaluate the Pharmacokinetics and Safety Between Single Administration of "BR6002" and Coadministration of "BR6002A" and "BR6002B" Under Fasting Conditions in Healthy Adult Volunteers (NCT05959486) | Boryung Pharmaceutical Co., Ltd | 2023-07-14 |
| A Study to Evaluate the Efficacy and Safety of BR1017A and BR1017B Combination Therapy in Essential Hypertension Patients With Primary Hypercholesterolemia (NCT05930028) | Boryung Pharmaceutical Co., Ltd | 2023-07-13 |
| A Study to Evaluate the Pharmacokinetics and Safety Between Single Administration of "BR6002" and Coadministration of "BR6002A" and "BR6002B" Under Fed Conditions in Healthy Adult Volunteers (NCT05959499) | Boryung Pharmaceutical Co., Ltd | 2023-07-13 |
| A Clinical Trial Study to Evaluate the Pharmacokinetic Interaction and Safety Between BR1019-1 and BR1019-2 in Healthy Adult Subjects (NCT05875259) | Boryung Pharmaceutical Co., Ltd | 2023-05-13 |
| An Observational Study to Analyze the Prescription Pattern of Sugammadex and Its Effectiveness and Safety (NCT05788718) | Boryung Pharmaceutical Co., Ltd | 2023-04-11 |
| A Study to Evaluate the Drug-drug Interaction and Safety Between "BR6001-1" and "BR6001-2" (NCT06165237) | Boryung Pharmaceutical Co., Ltd | 2023-03-30 |
| A Study to Evaluate the Efficacy and Safety of BR1015 Combination Therapy (NCT05878561) | Boryung Pharmaceutical Co., Ltd | 2022-11-09 |
| An OS to Evaluate the Safety & Efficacy of Fixed Dose Combination Therapy With Atorvastatin and Ezetimibe (NCT05559606) | Boryung Pharmaceutical Co., Ltd | 2022-09-07 |
| A Study to Evaluate the Pharmacokinetic Interaction and Safety Between BR1018-1 and BR1018-2 in Healthy Adult Subjects (NCT05460364) | Boryung Pharmaceutical Co., Ltd | 2022-08-04 |
| An OS to Evaluate Effectiveness and Safety of Fixed-dose Combinations of FMS/AML or FMS/AML/HCTZ (NCT05413057) | Boryung Pharmaceutical Co., Ltd | 2022-06-23 |
| A Study to Evaluate Drug-drug Interactions Between BR1017-1 and BR1017-2 in Healthy Volunteers (NCT05372380) | Boryung Pharmaceutical Co., Ltd | 2022-05-09 |
| A Study to Evaluate the Pharmacokinetics After Administration of BR3003 and Co-administration of BR3003B and BR3003C. (NCT05411965) | Boryung Pharmaceutical Co., Ltd | 2022-04-28 |
| A Clinical Trial to Compare the Pharmacokinetics and Safety of "BR1016C" With "BR1016D" in Healthy Volunteers (NCT05102266) | Boryung Pharmaceutical Co., Ltd | 2021-10-27 |
| A Clinical Trial to Compare the Pharmacokinetics and Safety of "BR1016A" With "BR1016B" in Healthy Volunteers (NCT05102903) | Boryung Pharmaceutical Co., Ltd | 2021-10-22 |
| An Observation Study to Evaluate the Renoprotective Effect of Fimasartan in Patients With DKD and Proteinuria (NCT05086549) | Boryung Pharmaceutical Co., Ltd | 2021-09-29 |
| A Multi-center,Prospective, OS to Evaluate the Effectiveness of 'NAC' Nebulizer Therapy in COPD (NEWEST) (NCT05102305) | Boryung Pharmaceutical Co., Ltd | 2021-09-09 |
| A Clinical Trial to Compare the Pharmacokinetics and Bioequivalence of "BR2008" With "BR2008-1" in Healthy Volunteers (NCT05068193) | Boryung Pharmaceutical Co., Ltd | 2021-09-06 |
| A Clinical Trial to Evaluate Drug-drug Interactions and Safety Between "BR1015-1" and "BR1015-2" in Healthy Volunteers (NCT05097794) | Boryung Pharmaceutical Co., Ltd | 2021-08-16 |
| A Multi Doses Study to Compare the Pharmacokinetics of BR9003A and BR9003 in Healthy Adult Subjects (NCT04857047) | Boryung Pharmaceutical Co., Ltd | 2021-03-31 |
| Evaluate the Quality of Life and Treatment of Anxiety Symptoms of Buspirone in Patients With Depression Disorders(BASIS) (NCT04770454) | Boryung Pharmaceutical Co., Ltd | 2021-02-08 |
| Good Choice of pALliative Chemotherapy to Patient With Pancreatic Cancer ; GemcitAbine Therapy vs FOLFORINOX therapY (NCT04789980) | Boryung Pharmaceutical Co., Ltd | 2021-01-29 |
| A Study to Evaluate Drug-drug Interactions Between BR9006-1 and BR9006-2 in Healthy Male Volunteers. (NCT04485585) | Boryung Pharmaceutical Co., Ltd | 2020-07-20 |
| Docetaxel Ethanol-induced Symptoms; The Incidence and Risk Forecating Factor (NCT04545632) | Boryung Pharmaceutical Co., Ltd | 2020-06-10 |
| A Study to Compare the Pharmacokinetics of BR4002 and BR4002-1 in Healthy Volunteers (NCT04462029) | Boryung Pharmaceutical Co., Ltd | 2020-06-05 |
| BR101801 in Adult Patients With Advanced Hematologic Malignancies(Phase I) (NCT04018248) | Boryung Pharmaceutical Co., Ltd | 2020-04-21 |
| A Combination Drug Including Fimasartan and Statins in Patients With Hypertension and Dyslipidemia (NCT04554953) | Boryung Pharmaceutical Co., Ltd | 2020-04-13 |
| Oxaliplatin Adjuvant Chemotherapy After Curative Resection of Primary Colon Cancer (NCT04416490) | Boryung Pharmaceutical Co., Ltd | 2020-03-25 |
| NAC Inhalation in the Treatment Of Symptomatic acuTe rhinosinUSitis (NCT04131686) | Boryung Pharmaceutical Co., Ltd | 2019-09-30 |
| BR1010 in Patients With Essential Hypertension Patients Who do Not Adequately Respond to Fimasartan/Amlodipine Combination (NCT03991442) | Boryung Pharmaceutical Co., Ltd | 2019-06-17 |
| VMP Regimen - Safety, Efficacy, and Optimal Dose Finding Study for Patients With Multiple Myeloma (NCT04151615) | Boryung Pharmaceutical Co., Ltd | 2018-11-15 |
| To Evaluate the Pharmacokinetics and Safety of Oral Administration of BR9001 Compared With BR900A in Healthy Subjects (NCT03718611) | Boryung Pharmaceutical Co., Ltd | 2018-10-22 |
| Combination of Fimasartan/Amlodipine/Hydrochlorothiazide in Healthy Male Subjects (NCT03629067) | Boryung Pharmaceutical Co., Ltd | 2018-09-13 |
| A Study to Evaluate the Efficacy and Safety of Combination Treatment of Fimasartan/Atorvastatin in Patients With Essential Hypertension and Dyslipidemia (NCT03338426) | Boryung Pharmaceutical Co., Ltd | 2018-01-15 |
| Drug Interaction Study of Fimasartan/Amlodipine/Hydrochlorothiazide in Healthy Male Subjects (NCT03390465) | Boryung Pharmaceutical Co., Ltd | 2017-12-15 |
| To Evaluate the Immunogenicity and Safety of Inactivated Hepatitis A Vaccine (VITHA-A) (NCT03654677) | Boryung Pharmaceutical Co., Ltd | 2017-09-19 |